SCHEMBL10197995

SCHEMBL10197995

CC(=O)C[C@@]1(N)CCc2ccc([N+](=O)[O-])cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.41
SIRT2 Q8IXJ6 2/20 0.40
DPP7 Q9UHL4 1/20 0.38
ADRA2A P08913 3/20 0.38
PNMT P11086 3/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
TLR9 Q9NR96 1/20 0.37
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 3/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
CYP3A4 P08684 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ALOX15 P16050 1/20 0.35
GLO1 Q04760 1/20 0.35
CA12 O43570 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL568062 0.89 MEN1 (0.42) AKR1B1SIRT2MEN1LMNAMAPT
SCHEMBL27901480 0.84 SMN1; SMN2 (0.40) AKR1B1SIRT2DPP7ADRA2APNMT
SCHEMBL8521894 0.80 SIRT2 (0.42) AKR1B1SIRT2DPP7ADRA2APNMT
Hydrochloric Acid SCHEMBL27486730 0.75 GRIN2B (0.44) MEN1MAPTKMT2ATLR9MAPK1
SCHEMBL22833739 0.72 PNMT (0.45) ADRA2APNMTMEN1LMNAMAPT
SCHEMBL29506344 0.72 PNMT (0.45) ADRA2APNMTMEN1LMNAMAPT
Ammonia Solution, Strong SCHEMBL29113467 0.72 PNMT (0.45) ADRA2APNMTMEN1LMNAMAPT
SCHEMBL14053942 0.71 ALDH1A1 (0.39) SIRT2ADRA2APNMTMEN1LMNA
SCHEMBL14053944 0.71 ALDH1A1 (0.39) SIRT2ADRA2APNMTMEN1LMNA
SCHEMBL18595788 0.70 PNMT (0.46) AKR1B1SIRT2ADRA2APNMTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 AKR1B1 344/4885SIRT2 143/4885DPP7 8/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 AKR1B1 344/4885SIRT2 143/4885DPP7 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.